Anti-TNF therapy attenuates the diagnostic utility of leucine-rich α2-Glycoprotein 1 for endoscopic activity in ulcerative colitis
Background Serum leucine-rich α2-glycoprotein1 (LRG1) is a promising biomarker for mucosal inflammation in ulcerative colitis (UC). However, because systemic LRG1 expression is partly tumor necrosis factor-α (TNF-α)-dependent, anti-TNF therapy may pharmacologically suppress its levels independently of mucosal status. O...